Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Respiratory Syncytial Virus (RSV) G protein is a major surface glycoprotein responsible for viral attachment to host cells. RSV is divided into two main antigenic subtypes, A and B, with the G protein being the most variable among RSV proteins and serving as a key determinant for subgroup classification. The subtype B G protein shares core structural and functional features with subtype A but exhibits distinct genetic sequences and antigenic properties. It mediates attachment of the virus to ciliated epithelial cells in the airways by binding to cell surface molecules such as glycosaminoglycans (GAGs) through heparin-binding domains (HBDs) and can bind CX3CR1 on airway epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory Syncytial Virus G Protein Subtype B (RSV G protein subtype B).